← Oncology Approval Tracker

FDA DECISION ·

Lyrfigtu

lirafugratinib · Elevar Therapeutics

FDA approvalNew therapyBiliary tract cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.

LAMPGEN ANALYSIS

Why it matters

This gives a molecularly selected biliary tract cancer population another FGFR-targeted option. REFOCUS enrolled patients without prior FGFR inhibitor treatment, which is important when discussing sequencing.

What research teams should watch

Make the FGFR2 fusion or rearrangement result retrievable across outside pathology, molecular labs and the study record. Keep prior FGFR inhibitor exposure separate from prior chemotherapy.

PRIMARY RECORDS

Sources